Sarcomas other than Kaposi sarcoma occurring in immunodeficiency:  interpretations from a systematic literature review.
OBJECTIVE
In immunodeficiency, an increased sarcoma risk is confirmed for Kaposi's sarcoma. Whether rates of other sarcoma subtypes are elevated in the setting of immunodeficiency is not known. We therefore reviewed published case reports on HIV and AIDS patients and organ transplant recipients with sarcomas. For comparison, we assessed sarcomas in the U.S. general population using Surveillance Epidemiology End Results (SEER) data.


RESULTS
A total of 176 non-Kaposi sarcoma were identified, 75 in people with HIV and AIDS and 101 in transplant recipients. Leiomyosarcomas (n = 101) were the most frequently reported sarcomas, followed by angiosarcomas (n = 23) and fibrohistiocytic tumors (n = 17). Leiomyosarcomas were reported with two age peaks, in children and young adults. Epstein-Barr virus (EBV) was detected in the tumor cells in 85 and 88% of leiomyosarcomas in HIV-infected people and transplant recipients, respectively. Angiosarcomas and fibrohistiocytic tumors were most frequently reported in men. Among kidney transplant recipients, 20% of sarcomas arose at the site of an arteriovenous fistula. In comparison, leiomyoscarcomas, angiosarcomas, and fibrohistiocytic tumors comprised 16.9, 3.8, and 18.7% of sarcomas in the U.S. general population.


CONCLUSIONS
Leiomyosarcoma and angiosarcoma may occur disproportionately in immunodeficiency. Leiomyosarcomas appear causatively linked to EBV, whereas angiosarcomas might be correlated with an arteriovenous fistula. Additional studies are necessary to understand the contribution of immunodeficiency to the cause of these sarcomas.
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. bhatiak@mail.nih.gov
Kishor
K
Bhatia
Meredith S
MS
Shiels
Alexandra
A
Berg
Eric A
EA
Engels
D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology / Q000276:immunology*; D015658:HIV Infections / Q000453:epidemiology / Q000276:immunology*; D006394:Hemangiosarcoma / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D051677:Histiocytoma, Malignant Fibrous / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D006801:Humans; D007890:Leiomyosarcoma / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D018426:SEER Program; D012509:Sarcoma / Q000453:epidemiology / Q000276:immunology* / Q000821:virology*; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D014481:United States / Q000453:epidemiology